{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T13:12:19Z","timestamp":1769087539710,"version":"3.49.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.cyto.2024.156529","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T05:45:19Z","timestamp":1707371119000},"page":"156529","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Antiviral treatment significantly reduces the levels of CXCL9, CXCL10 and CXCL11 in chronic hepatitis C"],"prefix":"10.1016","volume":"176","author":[{"given":"Leona","family":"Radmani\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"\u0160imi\u010di\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristian","family":"Boduli\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Vince","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Snjezana","family":"Zidovec-Lepej","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2024.156529_b0005","unstructured":"Hepatitis C [Internet]; Geneve; World Health Organization; c2022 [cited 2023 Aug 01]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"key":"10.1016\/j.cyto.2024.156529_b0010","doi-asserted-by":"crossref","first-page":"7824","DOI":"10.3748\/wjg.v22.i34.7824","article-title":"Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes","volume":"22","author":"Petruzziello","year":"2016","journal-title":"World J Gastroenterol."},{"key":"10.1016\/j.cyto.2024.156529_b0015","doi-asserted-by":"crossref","first-page":"159","DOI":"10.21101\/cejph.a5021","article-title":"Distribution of hepatitis C virus genotypes and subtypes in Croatia: 2008\u20132015","volume":"26","author":"Vince","year":"2018","journal-title":"Cent Eur J Public Health."},{"issue":"4","key":"10.1016\/j.cyto.2024.156529_b0020","first-page":"637","article-title":"Worldwide prevalence, genotype distribution and management of hepatitis C","volume":"84","author":"Guntipalli","year":"2021","journal-title":"Acta Gastroenterol Belg."},{"key":"10.1016\/j.cyto.2024.156529_b0025","unstructured":"Classification and genotype \/ subtype assignments of hepatitis C virus [Internet]; Paris; International Committee on Taxonomy of Viruses; c2022 [cited 2023 Aug 01]. Available from https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"key":"10.1016\/j.cyto.2024.156529_b0030","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.meegid.2013.10.021","article-title":"Phylogeny and molecular evolution of the hepatitis C virus","volume":"21","author":"Jackowiak","year":"2014","journal-title":"Infect Genet Evol."},{"issue":"9973","key":"10.1016\/j.cyto.2024.156529_b0035","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0140-6736(14)62401-6","article-title":"Hepatitis C","volume":"385","author":"Webster","year":"2015","journal-title":"Lancet."},{"key":"10.1016\/j.cyto.2024.156529_b0040","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.coviro.2018.10.005","article-title":"Viral resistance in HCV infection","volume":"32","author":"Ceccherini-Silberstein","year":"2018","journal-title":"Curr Opin Virol."},{"key":"10.1016\/j.cyto.2024.156529_b0045","first-page":"285","article-title":"Strategies to eliminate hepatitis C in Croatia, a modelling study","volume":"142","author":"Vince","year":"2020","journal-title":"Lijec Vjesn."},{"key":"10.1016\/j.cyto.2024.156529_b0050","unstructured":"Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection [Internet]; Geneve; World Health Organization; c2022 [cited 2023 Aug 01]. Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/246177\/WHO-HIV-2016.06-eng.pdf."},{"issue":"4","key":"10.1016\/j.cyto.2024.156529_b0055","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology."},{"issue":"5","key":"10.1016\/j.cyto.2024.156529_b0060","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jhep.2020.11.021","article-title":"Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity","volume":"74","author":"Krassenburg","year":"2021","journal-title":"J Hepatol."},{"issue":"1","key":"10.1016\/j.cyto.2024.156529_b0065","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3748\/wjg.v28.i1.96","article-title":"Risk of hepatocellular carcinoma after hepatitis C virus cure","volume":"28","author":"Luna-Cuadros","year":"2022","journal-title":"World J Gastroenterol."},{"issue":"1","key":"10.1016\/j.cyto.2024.156529_b0070","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cyto.2007.05.013","article-title":"Chemokines in hepatitis C virus infection: pathogenesis, prognosis and therapeutics","volume":"39","author":"Wald","year":"2007","journal-title":"Cytokine."},{"issue":"7258","key":"10.1016\/j.cyto.2024.156529_b0075","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1136\/bmj.321.7258.424","article-title":"Th1 and Th2 responses: what are they?","volume":"321","author":"Berger","year":"2020","journal-title":"BMJ."},{"issue":"3","key":"10.1016\/j.cyto.2024.156529_b0080","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1478-3231.1999.tb00038.x","article-title":"Hepatic stellate cell activation and liver fibrosis are associated with necroinflammatory injury and Th1-like response in chronic hepatitis C","volume":"19","author":"Baroni","year":"1999","journal-title":"Liver."},{"issue":"Suppl 2","key":"10.1016\/j.cyto.2024.156529_b0085","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1002\/lt.21644","article-title":"Virology and pathogenesis of hepatitis C virus recurrence","volume":"14","author":"Ram\u00edrez","year":"2008","journal-title":"Liver Transpl."},{"issue":"32","key":"10.1016\/j.cyto.2024.156529_b0090","doi-asserted-by":"crossref","first-page":"11033","DOI":"10.3748\/wjg.v20.i32.11033","article-title":"Chronic hepatitis C and liver fibrosis","volume":"20","author":"Sebastiani","year":"2014","journal-title":"World J Gastroenterol."},{"issue":"10","key":"10.1016\/j.cyto.2024.156529_b0095","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.3390\/cells8101249","article-title":"Mechanisms Underlying Hepatitis C Virus-Associated Hepatic Fibrosis","volume":"8","author":"Khatun","year":"2019","journal-title":"Cells."},{"issue":"4","key":"10.1016\/j.cyto.2024.156529_b0100","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3390\/cells9040875","article-title":"Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives","volume":"9","author":"Roehlen","year":"2020","journal-title":"Cells."},{"key":"10.1016\/j.cyto.2024.156529_b0105","unstructured":"Manel J, Colobran R. Chemokines and Chemokine Receptors. Encyclopedia of Life Sciences (ELS). 1st ed. John Wiley; Sons, Ltd; Chichester;2009."},{"issue":"4","key":"10.1016\/j.cyto.2024.156529_b0110","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/cmi.2017.134","article-title":"Chemokines in homeostasis and diseases","volume":"15","author":"Chen","year":"2018","journal-title":"Cell Mol Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2024.156529_b0115","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/hep.22763","article-title":"Chemokines in the immunopathogenesis of hepatitis C infection","volume":"49","author":"Heydtmann","year":"2009","journal-title":"Hepatology."},{"issue":"1","key":"10.1016\/j.cyto.2024.156529_b0120","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/cmi.2013.37","article-title":"The role of chemokines in acute and chronic hepatitis C infection","volume":"11","author":"Fahey","year":"2014","journal-title":"Cell Mol Immunol."},{"issue":"4","key":"10.1016\/j.cyto.2024.156529_b0125","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/hep.27971","article-title":"Temporal dynamics of inflammatory cytokines\/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection","volume":"62","author":"Carlin","year":"2015","journal-title":"Hepatology."},{"key":"10.1016\/j.cyto.2024.156529_b0130","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.26161","article-title":"Changes of inflammatory cytokines\/chemokines during ravidasvir plus ritonavir-boosted danoprevir and ribavirin therapy for patients with genotype 1b hepatitis C infection","author":"Xiao","year":"2020","journal-title":"J Med Virol."},{"key":"10.1016\/j.cyto.2024.156529_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105073","article-title":"Remodeling of immunological biomarkers in patients with chronic hepatitis C treated with direct-acting antiviral therapy","volume":"190","author":"Ribeiro","year":"2021","journal-title":"Antiviral Res."},{"issue":"8","key":"10.1016\/j.cyto.2024.156529_b0140","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.3390\/v14081613","article-title":"The Effect of Treatment-Induced Viral Eradication on Cytokine and Growth Factor Expression in Chronic Hepatitis C","volume":"14","author":"Radmani\u0107","year":"2022","journal-title":"Viruses."},{"key":"10.1016\/j.cyto.2024.156529_b0145","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C","volume":"24","author":"Bedossa","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.cyto.2024.156529_b0150","unstructured":"R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; Vienna; 2013. [cited 2023 Aug 01]. Available from: https:\/\/www.R-project.org\/."},{"issue":"11","key":"10.1016\/j.cyto.2024.156529_b0155","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1136\/gutjnl-2013-306098","article-title":"CCL20 mediates lipopolysaccharide induced liver injury and is a potential driver of inflammation and fibrosis in alcoholic hepatitis","volume":"63","author":"Aff\u00f2","year":"2014","journal-title":"Gut."},{"issue":"2","key":"10.1016\/j.cyto.2024.156529_b0160","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3233\/HAB-190400","article-title":"CXCL9 chemokine level is associated with spontaneous clearance and sustained virological response in Egyptian Chronic Hepatitis C patients receiving direct acting antivirals","volume":"28","author":"Tabll","year":"2020","journal-title":"Hum Antibiodies."},{"issue":"6","key":"10.1016\/j.cyto.2024.156529_b0165","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.clinre.2017.04.007","article-title":"Active HCV infection is associated with increased circulating levels of interferon-gamma (IFN-\u03b3)-inducible protein-10 (IP-10), soluble CD163 and inflammatory monocytes regardless of liver fibrosis and HIV coinfection","volume":"41","author":"Mascia","year":"2017","journal-title":"Clin Res Hepatol Gastroenterol."},{"key":"10.1016\/j.cyto.2024.156529_b0170","article-title":"IP-10 Interferes With the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection","volume":"10","author":"Wang","year":"2022","journal-title":"Front Public Health."},{"issue":"38","key":"10.1016\/j.cyto.2024.156529_b0175","doi-asserted-by":"crossref","first-page":"e12403","DOI":"10.1097\/MD.0000000000012403","article-title":"Patients with chronic hepatitis C receiving sofosbuvir and ribavirin-based treatment, with or without interferon in Zhejiang, China: An observational study","volume":"97","author":"Xu","year":"2018","journal-title":"Medicine (baltimore)."},{"key":"10.1016\/j.cyto.2024.156529_b0180","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","article-title":"CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation - a target for novel cancer therapy","volume":"63","author":"Tokunaga","year":"2018","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.cyto.2024.156529_b0185","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cyto.2019.02.006","article-title":"Circulating levels of CXCL11 and CXCL12 are biomarkers of cirrhosis in patients with chronic hepatitis C infection","volume":"117","author":"Chalin","year":"2019","journal-title":"Cytokine."},{"issue":"3","key":"10.1016\/j.cyto.2024.156529_b0190","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1440-1746.2010.06436.x","article-title":"CXCL5 plasma levels decrease in patients with chronic liver disease","volume":"26","author":"Tacke","year":"2011","journal-title":"J Gastroenterol Hepatol."},{"issue":"4","key":"10.1016\/j.cyto.2024.156529_b0195","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jaut.2010.09.003","article-title":"CXCL10 promotes liver fibrosis by prevention of NK cell mediated hepatic stellate cell inactivation","volume":"35","author":"Hintermann","year":"2010","journal-title":"J Autoimmun."},{"issue":"6","key":"10.1016\/j.cyto.2024.156529_b0200","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/infdis\/jir424","article-title":"CXCL9 and CXCL10 chemokines as predictors of liver fibrosis in a cohort of primarily African-American injection drug users with chronic hepatitis C","volume":"204","author":"Zeremski","year":"2011","journal-title":"J Infect Dis."},{"issue":"7","key":"10.1016\/j.cyto.2024.156529_b0205","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.4049\/jimmunol.173.7.4692","article-title":"The role of the Th2 CC chemokine ligand CCL17 in pulmonary fibrosis","volume":"173","author":"Belperio","year":"2004","journal-title":"J Immunol."},{"key":"10.1016\/j.cyto.2024.156529_b0210","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.637023","article-title":"CXCL5 Has Potential to Be a Marker for Hepatocellular Carcinoma Prognosis and Was Correlating With Immune Infiltrates","volume":"11","author":"Nie","year":"2021","journal-title":"Front Oncol."},{"issue":"7","key":"10.1016\/j.cyto.2024.156529_b0215","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3748\/wjg.v27.i7.641","article-title":"Effect of liver inflammation on accuracy of FibroScan device in assessing liver fibrosis stage in patients with chronic hepatitis B virus infection","volume":"27","author":"Huang","year":"2021","journal-title":"World J Gastroenterol."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466624000322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466624000322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:50:26Z","timestamp":1760910626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466624000322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":43,"alternative-id":["S1043466624000322"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2024.156529","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiviral treatment significantly reduces the levels of CXCL9, CXCL10 and CXCL11 in chronic hepatitis C","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2024.156529","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"156529"}}